VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS

Sponsor
Navy General Hospital, Beijing
Study ID
NCT06471946
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Higher-risk Myelodysplastic Syndromes

Eligibility Criteria

Sex
ALL
Age
70 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The goal of this phase 1/2 trial is to test the safety and efficacy of Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT in treating patients with higher-risk MDS.

Key Dates

Start date
Oct 1, 2024
Status verified
Sep 2024
Primary completion
Sep 1, 2029
Completion
Sep 1, 2030

Study Design

Enrollment
54 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT
    Patients were treated by Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT

Primary Outcome Measure

Overall Survival [ Time Frame: 3 year ]

Central Contacts

Related Studies